J&J Targets $100B+ Sales in 2026 as Growth Accelerates in Both Units

Key Takeaways JNJ forecasts 2026 sales of $100-$101B and adjusted EPS of $11.43$11.63 on accelerating segment growth.J&J expects Innovative Medicine growth despite Stelara LOE, supported by Darzalex, Tremfya and new launches.JNJ sees stronger MedTech growth in 2026 from new products, partly offset by China's VBP pressure.On its fourth-quarter earnings conference call on Jan. 21, Johnson & Johnson (JNJ) announced its financial outlook for 2026, which exceeded consensus expectations.J&J said it expects sales ...